MMP3 Monoclonal Antibody for Matrix Metalloproteinase-3 ELISA & CLIA IVD Development
MMP3 (Matrix Metalloproteinase-3), also known as stromelysin-1, is a zinc-dependent endopeptidase and a key member of the MMP family of extracellular matrix (ECM) remodeling enzymes. The MMP3 protein is secreted as a latent proenzyme (~54 kDa) and activated proteolytically to its active form (~45 kDa) by other MMPs or serine proteases. MMP3 has a broad substrate specificity, capable of degrading multiple ECM components including fibronectin, collagens (types II, III, IV, and V), laminin, nidogen, and proteoglycans such as aggrecan. It is primarily produced by activated synovial fibroblasts, chondrocytes, macrophages, and endothelial cells in response to pro-inflammatory cytokines — particularly interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) — which are the central mediators of joint inflammation in rheumatoid arthritis.
From a clinical diagnostics standpoint, serum MMP3 is a well-validated biomarker for rheumatoid arthritis (RA) disease activity and joint damage progression. In RA patients, serum MMP3 levels are significantly elevated above the reference ranges established for healthy adults (males: <121 ng/mL; females: <59 ng/mL), and these elevations directly correlate with the degree of synovial inflammation, cartilage destruction, and radiographic joint damage as measured by the Sharp/van der Heijde score. Importantly, serum MMP3 is included in Japanese RA management guidelines as a recommended monitoring biomarker — making MMP3 ELISA and CLIA testing a standard clinical laboratory test in Japan. In Europe and North America, MMP3 is increasingly incorporated into multimarker RA activity assessment panels alongside CRP (C-reactive protein), anti-CCP antibodies, RF (rheumatoid factor), and ESR to provide a more complete picture of disease activity and structural damage risk. The DAS28 composite score — the international standard for RA disease activity assessment — can be complemented by MMP3 data to improve prediction of radiographic progression.
For IVD assay development, MMP3 quantification uses a sandwich immunoassay format (ELISA or CLIA). MMP3-W253 is a high-purity (>95% by SDS-PAGE) mouse anti-human MMP3 monoclonal antibody suitable for use as capture or detection antibody in ELISA and CLIA sandwich assays. Its validated performance on ELISA, CLIA, and LFA platforms means that a single antibody source can supply multiple assay format development programs. Developers building MMP3 sandwich assays will pair MMP3-W253 with a second anti-MMP3 antibody targeting a non-overlapping epitope. Sekbio's technical team can advise on pairing strategy and antibody development through our hybridoma platform. Contact us to discuss a complete MMP3 assay development package.
High-purity anti-human MMP3 monoclonal antibody for ELISA, CLIA, and LFA sandwich immunoassay development.
| Catalog No. | Product Name | Type | Purity | Intended Use | Storage |
|---|---|---|---|---|---|
| MMP3-W253 | Mouse Anti-Human MMP3 Monoclonal Antibody | Antibody | ≥95% SDS-PAGE | Capture / Detection — ELISA, CLIA, LFA | +2–8°C / −80°C |
Supplied in PBS pH 7.4. MOQ 1 mg. For complete sandwich immunoassay development, contact info@sekbio.com to discuss antibody pairing strategies or custom antibody development through Sekbio's hybridoma platform.
Engineered for the sensitivity, specificity, and batch consistency required in clinical rheumatoid arthritis MMP3 diagnostics.
MMP3-W253 achieves ≥95% purity by SDS-PAGE — higher than the typical >90% threshold for many diagnostic antibodies. This exceptional purity minimizes non-specific binding in ELISA sandwich assays and CLIA microparticle platforms, reducing background signal and improving precision at clinically critical MMP3 concentrations (<100 ng/mL) for normal-range discrimination in RA monitoring.
MMP3-W253 is validated for ELISA (laboratory sandwich quantitative assay), CLIA (chemiluminescence immunoassay for automated analyzer platforms), and LFA (lateral flow assay for rapid point-of-care testing). This multi-platform compatibility means that IVD developers can use the same antibody source for both hospital laboratory quantitative MMP3 testing and rapid MMP3 screening strip development — simplifying raw material sourcing and regulatory documentation.
Serum MMP3 is a standard RA monitoring biomarker in Japan, where it is listed in Japanese Society of Clinical Rheumatology guidelines alongside CRP and anti-CCP for disease activity and joint damage tracking. The Japanese RA diagnostics market is one of the largest MMP3 testing markets globally. MMP3-W253 supports IVD manufacturers developing ELISA and CLIA kits targeting the Japanese, Korean, and European rheumatology markets.
Manufactured under ISO 13485 QMS with inter-batch coefficient of variation <10%. Each lot undergoes appearance inspection, SDS-PAGE purity confirmation (≥95%), and bioreactivity QC by antigen binding ELISA before release. Consistent lot performance enables straightforward assay re-validation during OEM production scale-up and simplifies CE-IVD technical file documentation for batch traceability requirements.
Serum MMP3 is a pharmacodynamic marker for RA disease-modifying antirheumatic drug (DMARD) therapy and biologic treatment response. Effective RA treatment (methotrexate, TNF inhibitors, IL-6 inhibitors) is associated with measurable MMP3 reduction. MMP3-W253-based CLIA and ELISA kits enable rheumatology clinics and clinical trial laboratories to monitor biologic treatment response — an increasingly important use case as JAK inhibitor and biologic treatment adoption grows in RA management.
MOQ 1 mg for R&D evaluation; gram-scale OEM production available. For complete MMP3 sandwich assay development, Sekbio's technical team can advise on pairing antibody sourcing and provide custom antibody development through our hybridoma discovery platform. We support CE, NMPA, and FDA regulatory submission documentation. Contact info@sekbio.com to discuss your MMP3 IVD kit development project.
MMP3 sandwich immunoassay antibody for rheumatoid arthritis management, joint damage prediction, and RA therapeutic monitoring kit development.
Serum MMP3 quantification is a core component of RA disease activity monitoring in Japan and is increasingly adopted in European and Korean rheumatology practice. MMP3 elevation above reference ranges (males: <121 ng/mL; females: <59 ng/mL) indicates active synovial inflammation and elevated risk of radiographic joint destruction. MMP3-W253-based ELISA kits provide clinical rheumatology laboratories with a quantitative, reproducible MMP3 measurement tool for routine RA monitoring visits and treatment decision support — complementing DAS28 composite scores and acute-phase reactant testing.
Elevated serum MMP3 is independently associated with progressive radiographic joint destruction in RA patients. MMP3 levels above the upper normal limit correlate with higher annualized Sharp/van der Heijde scores in longitudinal cohort studies, making MMP3 a prognostic marker for structural damage risk. IVD manufacturers developing comprehensive RA management panels — combining anti-CCP antibody, CRP, and MMP3 quantification — can use MMP3-W253 for the MMP3 ELISA or CLIA component, enabling a single-vendor antibody source across multiple RA biomarkers with Sekbio's broader immunoreagent portfolio.
Serum MMP3 is a validated pharmacodynamic biomarker for RA treatment response. Effective DMARD therapy (methotrexate, leflunomide) and biologic treatments (TNF inhibitors: etanercept, adalimumab; IL-6 inhibitors: tocilizumab; JAK inhibitors: tofacitinib, baricitinib) are all associated with dose-dependent MMP3 reduction. Clinical trials routinely measure serum MMP3 as a secondary endpoint for joint protection assessment. MMP3-W253-based CLIA assays support both clinical laboratory monitoring and pharmaceutical clinical trial biomarker testing, broadening the commercial application base for MMP3 IVD kit products.
Beyond clinical RA diagnostics, MMP3-W253 is suitable for research-use-only (RUO) ELISA development for MMP3 research in osteoarthritis, cardiovascular disease (MMP3 in atherosclerotic plaque), cancer biology (MMP3 in tumor invasion and metastasis), and fibrotic disease. Academic research groups and pharmaceutical companies studying ECM remodeling, inflammation, or cancer biology can deploy MMP3-W253 in custom ELISA assay formats. Visit our Platforms page for custom antibody and assay development services, or contact our team for technical consultation.
Technical and commercial questions from IVD R&D engineers and procurement teams developing MMP3 diagnostic assays.
MMP3 (Matrix Metalloproteinase-3 / stromelysin-1) is a zinc-dependent protease (~54 kDa proenzyme, ~45 kDa active form) that degrades fibronectin, collagens II/III/IV/V, laminin, and proteoglycans. It is produced by synovial fibroblasts and chondrocytes in response to IL-1β and TNF-α in inflamed joints. Serum MMP3 is significantly elevated in RA patients and correlates with disease activity (DAS28) and radiographic joint damage progression. Japan's RA management guidelines recommend MMP3 as a standard monitoring biomarker. Reference ranges: males <121 ng/mL, females <59 ng/mL.
Sekbio supplies MMP3-W253: Mouse Anti-Human MMP3 monoclonal antibody (clone), ≥95% purity by SDS-PAGE, PBS pH 7.4 buffer, validated for ELISA, CLIA, and LFA platforms. Available from MOQ 1 mg with Certificate of Analysis. For sandwich immunoassay development, MMP3-W253 serves as capture or detection antibody, paired with a second anti-MMP3 antibody targeting a distinct epitope.
MMP3-W253 is validated for three immunoassay platforms: ELISA (sandwich format for quantitative laboratory testing), CLIA (chemiluminescence immunoassay for automated analyzers), and LFA (lateral flow assay for rapid testing). The antibody can function as either capture or detection antibody depending on the pairing configuration and platform requirements. This multi-platform validation enables a single raw material source for both hospital laboratory quantitative testing and POCT lateral flow strip development.
MMP3-W253 storage: +2°C to +8°C for short-term use; −80°C for long-term storage. Supplied in PBS pH 7.4. Avoid repeated freeze/thaw cycles to maintain antibody integrity. Purity ≥95% by SDS-PAGE confirmed by QC. Inter-batch CV <10%. Full Certificate of Analysis with each lot. Shelf life: please refer to the Certificate of Analysis label date.
MOQ is 1 mg for R&D evaluation. OEM quantities from 10 mg to gram scale are available for IVD kit manufacturing. Sekbio's ISO 13485-certified Shenzhen manufacturing delivers consistent ≥95% purity lots for CE-marked RA diagnostic kit production. MMP3 ELISA/CLIA kits are in demand in the Japanese, Korean, and European rheumatology markets. Contact info@sekbio.com for bulk pricing and OEM supply agreements.
Sekbio currently provides MMP3-W253 as the high-purity core antibody component. For complete MMP3 sandwich ELISA or CLIA assay development, a second antibody targeting a non-overlapping MMP3 epitope is required. Sekbio's technical team can advise on pairing strategies and, where needed, develop custom anti-MMP3 antibodies through our hybridoma discovery and antibody development platform. Visit our Platforms page or contact info@sekbio.com to discuss complete MMP3 assay development support.
Request the full technical datasheet, antibody specifications, or discuss OEM supply and pairing strategy with our team.